Alberto Foncillas

Dr. Alberto Foncillas

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2026 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
AFAlberto Foncillas
Alberto Foncillas
JAJuan Ambrosioni
Juan Ambrosioni
ASAbiu Sempere
Abiu Sempere
LBLeire Berrocal
Leire Berrocal
JJJúlia Calvo Jimenez
Júlia Calvo Jimenez
MLMontserrat Laguno
Montserrat Laguno
Background: Long-acting cabotegravir/rilpivirine (LA-CAB/RPV) therapy for HIV, lacks activity against hepatitis B virus (HBV). We evaluate HBV serological profiles and risk of HBV reactivation (HBVr) or incident infection (HBVi) in people with HIV (PWH) switching to LA-CAB/RPV. Methods: Prospective cohort study of PWH initiating LA-CAB/RPV at Hospital Clínic Barcelona between February/2023 and February/2025. HBV serology, vaccination status, and liver function tests (LFTs) were assessed at baseline. Follow-up LFTs were performed routinely (weeks 12, 28, and every 6 months), and HBV serology/DNA assessed if abnormal LFTs, acute hepatitis or clinical suspicion of reactivation. HBVr was defined as conversion from HBsAg negative to positive or detectable HBV DNA in anti-HBc-positive/HBsAg-negative individuals, or as HBV DNA ≥1 log increase or ≥100 IU/mL in chronic HBV (HBsAg-positive) participants. HBVi was defined as HBsAg seroconversion in HBV unexposed individuals. Results: Among 741 participants-92% cis-gender male, median age 43 (IQR 35–52)-454 (61%) had vaccine-induced immunity and 25% had prior HBV exposure (anti-HBc-positive), with 3% showing isolated anti-HBc. Median follow-up was 54 weeks (IQR 28–77). No HBVr or HBVi were observed in people without chronic hepatitis at baseline. Four individuals (0.5%) with unnoticed chronic HBV infection (HBsAg-positive) started LA-CAB/RPV; two developed clinical HBVr and two remained stable after regimen switch, all four switched back to tenofovir-containing therapy. Transaminase elevations during follow-up occurred in 17% of the cohort, regardless of HBV serostatus. Conclusions: LA-CAB/RPV appears safe in individuals with prior HBV exposure, including isolated anti-HBc. Comprehensive HBV screening, vaccination, and liver monitoring are essential.

7 November 2024 in HIV Medicine
Verified
Journal Article
Open access
MLMontserrat Laguno
Montserrat Laguno
ELElisa De Lazzari
Elisa De Lazzari
LBLeire Berrocal
Leire Berrocal
AIAlexy Inciarte
Alexy Inciarte
MMMaria Martinez-Rebollar
Maria Martinez-Rebollar
EMEsteban Martínez
Esteban Martínez
Background: Liver steatosis (LS) and liver fibrosis (LF) can increase the risk of cardiovascular disease in people with HIV, but their prevalence and associated factors are poorly understood. This study aimed to assess the prevalence of and factors associated with LS and LF in a large cohort of people with HIV. Methods: We conducted a cross‐sectional study of consecutive people with HIV attending the Clinic of Barcelona from September 2022 to September 2023, excluding those with chronic B or/and C hepatitis virus coinfection. LS was assessed using the Hepatic Steatosis Index (HSI) and Fatty Liver Index (FLI), and LF was assessed using the Non‐Alcoholic Fatty Liver Disease Fibrosis Score (NFS), Fibrosis‐4 score (FIB‐4), and the European AIDS Clinical Society (EACS) algorithm in both the whole cohort (cohort 1) and in a specific cohort more susceptible to liver disease (cohort 2). We identified independent variables associated with LS and LF using logistic regression. Results: Cohort 1 included 4664 people with HIV; 76% and 37% of them had available HSI and FLI data, LS was present in 28% and 19%, respectively. LF risk was present in 1%, 2%, and 1% of people with HIV according to NFS, FIB‐4, and EACS algorithm scores, respectively. Cohort 2 included 1345 people with HIV; 60% and 30% of them had available HSI and FLI data, LS affected 55% and 43% and LF 2%, 5%, or 3%, respectively. Factors associated with LS included current CD4 cell count, diabetes, and hypertension, whereas LF was associated with previous exposure to dideoxynucleoside drugs and current CD4 to LF. Current integrase strand transfer inhibitor (INSTI) therapy appeared protective for LF in cohort 1. Conclusions: In this study, one in four people with HIV had LS, and the prevalence rose to one in two in those with cardiovascular risk factors. The prevalence of LF was low, but it should be considered in older people with HIV with low CD4 counts or high aspartate transaminase levels. A possible protective effect from INSTIs deserves further investigation.

7 May 2026 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
AFAlberto Foncillas
Alberto Foncillas
JAJuan Ambrosioni
Juan Ambrosioni
LMLorena de la Mora
Lorena de la Mora
JMJosep Mallolas
Josep Mallolas
AGAna González-Cordón
Ana González-Cordón
MLMontserrat Laguno
Montserrat Laguno

19 August 2026 in Clinical Infectious Diseases
Verified
Journal Article
Open access
ICIván Chivite
Iván Chivite
MMM J Merino-Peñas
M J Merino-Peñas
AGAna González-Cordón
Ana González-Cordón
MMMaria Martinez-Rebollar
Maria Martinez-Rebollar
BTBerta Torres
Berta Torres
MLMontserrat Laguno
Montserrat Laguno
Background: Increasing heterogeneity among people with HIV requires evaluation of new follow-up strategies tailored to clinical/social complexity. Methods: Prospective, single-center, randomized, noninferiority trial comparing semi-annual standard of care (SoC) with annual follow-upover 24 months in virologically suppressed people with HIV with low-complexity profile according to the GeSIDA HIV Patient Stratification System. The primary endpoint was noninferiority (prespecified lower margin: −4%) in virological control (viral load <50 copies/mL; FDA snapshot). Secondary outcomes included adherence, quality of life, satisfaction, and healthcare costs. Results: Of 394 eligible candidates, 71 declined participation (48% preferred SoC) and 321 were randomized (162 SoC, 159 Annual). Participants were predominantly male (89%), men who have sex with men (78%), Spanish (63%), with a median age of 45 years and 13 years of HIV follow-up, without baseline differences between groups. Overall, 283 (88%) completed the study; 25 switched to long-acting therapy and 10 were lost or transferred. Virological control was similar in SoC and annual arms: 86.42% vs 86.79% (intention to treat) and 98.29% vs 97.87% (per protocol), although noninferiority was not statistically demonstrated. The proportion of highly satisfied participants increased significantly from baseline to 24 months in the annual arm (P = .001). Reductions in HIV-related direct costs (−25.3%; P < .001) were greater in the Annual group. Conclusions: Among people with HIV and low complexity, annual follow-up achieved virological outcomes clinically comparable to semi-annual care, despite not meeting the formal noninferiority threshold. Annual follow-up was associated with a significant increment in patient satisfaction and lower HIV-related direct costs.

23 May 2026 in Infectious Diseases and Therapy
Verified
Journal Article
Open access
AFAlberto Foncillas
Alberto Foncillas
LMLorena De La Mora
Lorena De La Mora
LBLeire Berrocal
Leire Berrocal
ELElisa de Lazzari
Elisa de Lazzari
JCJúlia Calvo
Júlia Calvo
JAJuan Ambrosioni
Juan Ambrosioni
The increasing adoption of tenofovir (TXF)-sparing antiretroviral therapy (ART) raises concerns regarding hepatitis B virus (HBV) susceptibility and reactivation risk among people with HIV (PWH). We characterized HBV serological profiles and vaccination status according to ART composition in a real-world cohort. A cross-sectional study of all PWH in active follow-up at Hospital Clínic, Barcelona, as of 30 June 2025. ART regimens were categorized as TXF-containing or TXF-sparing, with or without lamivudine (3TC). HBV serological patterns were classified as chronic infection, serologically resolved infection, isolated HBV core antibody (anti-HBc), no exposure/immunity, and vaccine-induced immunity. Demographic and clinical characteristics were compared using nonparametric and chi-squared/Fisher's tests. Among the 6437 participants included (82% cisgender men; median age 48 years [IQR 39-58]), 3519 (55%) received TXF-containing and 2918 (45%) TXF-sparing regimens, of whom 1702/2918 (58%) were with 3TC. HBV serological distribution was: 2% chronic infection, 26% serologically resolved infection, 5% isolated anti-HBc, 52% vaccine-induced immunity, and 15% without exposure/immunity (50% documented prior vaccination attempts, 32% nonresponders, and 31% with prior anti-HBs detection). Overall, 1280 (20%) lacked protective HBV immunity (isolated anti-HBc or negative serology for all markers), including 530 (41%) on TXF-free regimens. TXF recipients were younger (47 versus 50 years, p < 0.001), more often migrants (58% versus 49%, p < 0.001), had lower suppression rates (91% versus 97%, p < 0.001), a higher proportion of previous virological failure(s) (26% versus 21%, p < 0.001), and a lower number of prior ART regimens (median 3 versus 4, p < 0.001). One in five PWH lacked effective HBV immunity, including 41% of whom were receiving TXF-sparing strategies. In the context of increasing use of TXF-sparing strategies, improvements in systematic HBV screening, vaccination, and risk-based monitoring are essential to prevent HBV-related morbidity.

11 September 2026 in HIV Medicine
Verified
Journal Article
Open access
PDF file
AIAlexy Inciarte
Alexy Inciarte
EZElizabeth Zamora‐Clemente
Elizabeth Zamora‐Clemente
LBLeire Berrocal
Leire Berrocal
AGAna González-Cordón
Ana González-Cordón
LMLorena De La Mora
Lorena De La Mora
JMJosep Mallolas
Josep Mallolas
Objectives: To describe the sociodemographic characteristics, migration patterns and immunovirological outcomes of Venezuelan migrants living with HIV (PLWH) in Barcelona, Spain, and to compare them with other Latin American (LA) migrant PLWH. Methods: We conducted a retrospective observational cohort study including LA migrant PLWH who attended their first consultation at the HIV Unit of Hospital Clínic de Barcelona between 2000 and 2023. Venezuelan PLWH were compared with other LA migrant PLWH regarding demographics, HIV diagnosis timing, CD4 cell count, viral load, late HIV diagnosis (LHD) and advanced HIV disease (AHD). Results: A total of 493 Venezuelan PLWH were included, representing 16% of LA migrant PLWH in the cohort. Venezuelan PLWH were predominantly men (97%; n = 478). Most first consultations occurred after 2014 (81%; n = 399), peaking in 2018. Half were diagnosed with HIV after arrival in Spain (50%; 224/451), and 73% (328/451) had lived in Spain for less than 3 years. Among ART‐naïve individuals, LHD was 38% in 2000–2008 and 53% in 2015–2023, while baseline CD4 counts progressively declined. Immunological outcomes were similar between Venezuelan and other LA migrants, including LHD (50%; n = 98 vs. 51%; n = 622) and AHD (24%; n = 48 vs. 25%; n = 301). However, ART‐experienced Venezuelan PLWH showed lower virological suppression rates (67%; n = 191 vs. 72%; n = 1013; p = 0.068). Conclusion: Venezuelan PLWH in this Barcelona cohort represent a rapidly growing migrant population shaped by humanitarian displacement and disruption of HIV care. The high proportion of LHD and lower virological suppression among ART‐experienced individuals is compatible with continuity‐of‐care disruptions before migration but do not establish causality.